leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical files provisional patent application in Australia seeking protection for cannabinoid formulations to prevent and treat COVID-19

PreveCeutical and its Australian partner are now developing a Sol-gel CBD formula delivered via a nose applicator

PreveCeutical Medical Inc. - PreveCeutical Medical Inc files provisional patent application in Australia seeking protection for certain cannabinoid formulations to prevent and treat COVID-19
The Vancouver-based company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain COVID-19 at this time

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H) has filed a provisional patent application in Australia with the aim of seeking protection for certain cannabinoid formulations to prevent and treat the COVID-19 disease caused by the SARS-CoV-2 virus. 

"This patent is a very important patent addition to our library of intellectual properties (IP),” said CEO Stephen Van Deventer in a statement Monday. “The provisional application filing for this application will protect our cannabinoid Sol-gel IP as we prepare for clinical trials and commercialization of this formulation." 

The Vancouver-based company said it is not making any express or implied claims that its product has the ability to eliminate, cure, or contain COVID-19 at this time. 

READ: PreveCeutical Medical advancing its coronavirus (COVID-19) Cannabinoid Sol-Gel Program

The application, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use," was filed on November 20 with the Australian Patent Office.

Amid the coronavirus pandemic, PreveCeutical and its Australian partner are now developing a sol-gel CBD formula. With the use of a nose applicator, the sustained-released Sol-Gel formulations allows for the direct and prolonged delivery of cannabinoids to a patient's central nervous system. The program is designed to prevent SARS-CoV-2 infection in nasal tissue.

PreveCeutical also has developed Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: PreveCeutical Medical Inc.

Price: 0.03 CAD

CSE:PREV
Market: CSE
Market Cap: $14.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read